4-(2-chlorophenyl)-2-(2-(4-isobutylphenyl)ethyl)-6,9-dimethyl-6h-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine has been researched along with atropine in 1 studies
Studies (4-(2-chlorophenyl)-2-(2-(4-isobutylphenyl)ethyl)-6,9-dimethyl-6h-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine) | Trials (4-(2-chlorophenyl)-2-(2-(4-isobutylphenyl)ethyl)-6,9-dimethyl-6h-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine) | Recent Studies (post-2010) (4-(2-chlorophenyl)-2-(2-(4-isobutylphenyl)ethyl)-6,9-dimethyl-6h-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine) | Studies (atropine) | Trials (atropine) | Recent Studies (post-2010) (atropine) |
---|---|---|---|---|---|
51 | 1 | 8 | 26,711 | 1,259 | 1,697 |
Protein | Taxonomy | 4-(2-chlorophenyl)-2-(2-(4-isobutylphenyl)ethyl)-6,9-dimethyl-6h-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine (IC50) | atropine (IC50) |
---|---|---|---|
cystic fibrosis transmembrane conductance regulator | Homo sapiens (human) | 21.41 | |
5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 1.012 | |
Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.0067 | |
Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.0007 | |
Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | 0.001 | |
Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | 0.001 | |
Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | 0.001 | |
Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | 0.001 | |
Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.0009 | |
Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | 0.001 | |
Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.0015 | |
Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.0021 | |
Alpha-1D adrenergic receptor | Homo sapiens (human) | 1.354 | |
5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 1.012 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kawazoe, Y; Mizuta, H; Sagara, K; Shibata, M; Yamada, I | 1 |
1 other study(ies) available for 4-(2-chlorophenyl)-2-(2-(4-isobutylphenyl)ethyl)-6,9-dimethyl-6h-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine and atropine
Article | Year |
---|---|
Gastrointestinal physiology-regulated dogs: utilization of a bioavailability study of a new thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]-diazepine, an antagonist of platelet-activating factor, and its preparations.
Topics: Administration, Oral; Animals; Atropine; Azepines; Biological Availability; Chromatography, High Pressure Liquid; Dogs; Dosage Forms; Humans; Injections, Intravenous; Intestinal Absorption; Male; Pentagastrin; Platelet Activating Factor; Solubility; Tablets; Triazoles | 1994 |